Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Neuroone Medical Technologies (NMTC) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Neuroone Medical Technologies (NMTC) over the last 14 years, with Q4 2025 value amounting to $3.3 million.

  • Neuroone Medical Technologies' Operating Expenses rose 184.88% to $3.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $12.4 million, marking a year-over-year decrease of 78.59%. This contributed to the annual value of $12.4 million for FY2025, which is 461.94% down from last year.
  • Latest data reveals that Neuroone Medical Technologies reported Operating Expenses of $3.3 million as of Q4 2025, which was up 184.88% from $2.9 million recorded in Q3 2025.
  • In the past 5 years, Neuroone Medical Technologies' Operating Expenses registered a high of $3.8 million during Q2 2023, and its lowest value of $2.4 million during Q1 2021.
  • Moreover, its 5-year median value for Operating Expenses was $3.1 million (2024), whereas its average is $3.1 million.
  • In the last 5 years, Neuroone Medical Technologies' Operating Expenses soared by 3625.67% in 2023 and then tumbled by 1806.46% in 2024.
  • Neuroone Medical Technologies' Operating Expenses (Quarter) stood at $2.8 million in 2021, then increased by 15.15% to $3.2 million in 2022, then increased by 13.31% to $3.7 million in 2023, then fell by 12.06% to $3.2 million in 2024, then rose by 1.85% to $3.3 million in 2025.
  • Its Operating Expenses stands at $3.3 million for Q4 2025, versus $2.9 million for Q3 2025 and $2.8 million for Q2 2025.